PlainRecalls
FDA Drug Moderate Class II Ongoing

Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01

Reported: February 5, 2025 Initiated: January 17, 2025 #D-0213-2025

Product Description

Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01

Reason for Recall

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Details

Recalling Firm
McKesson
Units Affected
192 vials
Distribution
Nationwide USA
Location
Irving, TX

Frequently Asked Questions

What product was recalled?
Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01. Recalled by McKesson. Units affected: 192 vials.
Why was this product recalled?
cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 5, 2025. Severity: Moderate. Recall number: D-0213-2025.